An Actos class action lawsuit has been filed in a Canadian court against the drug’s manufacturer on behalf of a Toronto woman who was treated with the drug and died in April 2011 after a two-year battle with bladder cancer. The lawsuit alleges Takeda Pharmaceuticals failed to properly warn patients of the increased risks of bladder cancer that they may face when taking Actos for more than one year.
Approved by the Food and Drug Administration in 1999, Actos is designed to treat patients with type II diabetes. According to research conducted by the agency, patients taking Actos for more than one year may be up to 40% more likely to develop bladder cancer.
A French study linking the drug to bladder cancer prompted European officials to take Actos off the market. The Food and Drug Administration issued an updated warning in August 2011, but has not issued any plans to announce an Actos recall.